Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30338
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLe, Ngan-
dc.contributor.authorLuk, Ian-
dc.contributor.authorChisanga, David-
dc.contributor.authorShi, Wei-
dc.contributor.authorPang, Lokman-
dc.contributor.authorScholz, Glen-
dc.contributor.authorMariadason, John M-
dc.contributor.authorErnst, Matthias-
dc.contributor.authorHuynh, Jennifer-
dc.date2022-
dc.date.accessioned2022-06-23T00:38:06Z-
dc.date.available2022-06-23T00:38:06Z-
dc.date.issued2022-07-
dc.identifier.citationCytokine 2022-07; 155: 155887en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30338-
dc.description.abstractInterleukin-36 gamma (IL-36G) is a member of the IL-36 subfamily of cytokines and acts as a potent driver of inflammation. IL-36G has been extensively characterized in the pathogenesis of psoriasis and has been recently described to play roles in wound healing particularly in the gastrointestinal tract. However, the effects of IL-36G during cancer development including gastric cancer remain unexplored. Here, we show that IL-36G induced ERK1/2 activation in AGS, MKN1 and MKN45 human gastric cancer cell lines. Moreover, IL-36G induced colony formation, migration and invasion of these gastric cancer cell lines that was inhibited by the natural antagonist, IL-36 receptor antagonist (RA). Interrogation of TCGA stomach adenocarcinoma patient datasets revealed highly elevated IL-36G gene expression in human gastric cancer compared to normal tissue independent of tumor stage, and high IL-36G expression corresponded with poorer patient survival. Collectively, our results indicate for the first time that IL-36G supports a neoplastic phenotype in human gastric cancer cells.en
dc.language.isoeng
dc.subjectCytokinesen
dc.subjectGastric canceren
dc.subjectIL-36Gen
dc.subjectInterleukinsen
dc.titleIL-36G promotes cancer-cell intrinsic hallmarks in human gastric cancer cells.en
dc.typeJournal Articleen
dc.identifier.journaltitleCytokineen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationSchool of Computing and Information Systems, The University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.affiliationMelbourne Dental School, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, VIC, Australiaen
dc.identifier.affiliationLa Trobe University School of Cancer Medicine, VIC, Australiaen
dc.identifier.doi10.1016/j.cyto.2022.155887en
dc.type.contentTexten
dc.identifier.pubmedid35512531
local.name.researcherErnst, Matthias
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Dec 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.